VolitionRx Reports High Accuracy in Feline Cancer Blood Test Study, Advancing Liquid Biopsy for Cats

VolitionRx Limited (NYSE American: VNRX) announced the submission of a clinical manuscript for peer review that demonstrates the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats. The study, which has been submitted to a peer-reviewed journal, showed that the blood-based liquid biopsy test achieved 97% specificity and identified 86% of feline lymphoma cases. The company expects the publication to unlock a $5 million contractual milestone payment, further advancing the development of a commercial product for the companion animal oncology market.

The Nu.Q Vet technology is designed to detect circulating nucleosomes associated with cancer, offering a non-invasive diagnostic option for cats. Lymphoma is one of the most common cancers in cats, and current diagnostic methods often require invasive procedures such as biopsies. The high specificity and sensitivity reported in the study suggest that the test could significantly improve early detection and monitoring of the disease, potentially leading to better outcomes for feline patients. VolitionRx emphasized that this technology addresses a significant unmet need in veterinary medicine and represents a substantial commercial opportunity, with potential milestone payments and future revenue generation as the company works toward product commercialization.

VolitionRx is a multinational company focused on advancing the science of epigenetics, developing simple, cost-effective blood tests for early detection and monitoring of diseases in both humans and animals. The company's research and development activities are centered in Belgium, with additional operations in the U.S. and the U.K. The feline cancer test is part of Volition's broader portfolio of Nu.Q assays, which also target human cancers and diseases associated with NETosis, such as sepsis.

The announcement highlights the growing market for companion animal oncology, where pet owners increasingly seek advanced diagnostic options for their animals. According to the company, the successful commercialization of the Nu.Q Vet test could position VolitionRx as a key player in this expanding sector. The $5 million milestone payment, contingent on peer-reviewed publication, underscores the value placed on clinical validation by the company's partners. For more details, the full press release is available at https://ibn.fm/ARsEY.

VolitionRx's commitment to animal health is part of its broader mission to save lives and improve outcomes for both people and animals through earlier disease detection. The company's website, www.Volition.com, provides further information on its product pipeline and research initiatives. As the manuscript undergoes peer review, the veterinary community and investors will be watching closely for the final publication, which could pave the way for a new standard of care in feline oncology.